CUDC‐907 blocks multiple pro‐survival signals and abrogates microenvironment protection in CLL

CUDC‐907, a dual PI3K/HDAC inhibitor, has been proposed to have therapeutic potential in hematopoietic malignancies. However, the molecular mechanisms of its effects in chronic lymphocytic leukaemia (CLL) remain elusive. We show that CLL cells are sensitive to CUDC‐907, even under conditions similar...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of cellular and molecular medicine 2019-01, Vol.23 (1), p.340-348
Hauptverfasser:	Chen, Yixiang, Peubez, Chloé, Smith, Victoria, Xiong, Shiqiu, Kocsis‐Fodor, Gabriella, Kennedy, Ben, Wagner, Simon, Balotis, Constantine, Jayne, Sandrine, Dyer, Martin J. S., Macip, Salvador
Format:	Artikel
Sprache:	eng
Schlagworte:	1-Phosphatidylinositol 3-kinase AKT protein Antineoplastic Agents - pharmacology Apoptosis APRIL protein B-Cell Activating Factor - metabolism Blood cancer BLyS protein CCL3 protein Cell Survival - drug effects Chemokines Chemokines - metabolism Chronic lymphocytic leukemia CLL CXCR4 protein Cytokines HDAC Histone deacetylase Humans Inhibitors Leukemia Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - metabolism Leukemia, Lymphocytic, Chronic, B-Cell - pathology Low concentrations Lymphocytes Lymphocytes T microenvironment Molecular modelling Morpholines - pharmacology NF-kappa B - metabolism Original Phosphoinositide-3 Kinase Inhibitors Phosphorylation PI3K Proteins Pyrimidines - pharmacology Raf protein Receptors, CXCR4 - metabolism Signal transduction Signal Transduction - drug effects Stat3 protein Tumor Cells, Cultured Tumor Microenvironment - drug effects Tumor Necrosis Factor Ligand Superfamily Member 13 - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!